Comparative study of improving quality of sleep according to the method of ilaprazole administration for the treatment of Laryngopharyngeal reflux disease

A comparative study of Efficacy of Ilaprazole administration on Laryngopharyngeal reflux disease and Quality of Sleep.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003450

Enrollment

100

Registered

2019-01-25

Start date

2019-02-12

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : The Improvement of Laryngopharyngeal reflux symptom and sleep quality either by administration of Ilaprazole one 10mg pill twice a day or two 10mg pills once a day on patient with Laryngopharyn

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients whose RSI and RFS values are above 14 and 8, and diagnosed with Laryngopharyngeal reflux disease by laryngeal endoscopic finding.

Exclusion criteria

Exclusion criteria: -Those who are sensitive to Proton Pump Inhibitor (PPI) -Those who have taken anti reflux medication, Prokinetics or H2-blocker within one month. -Those who had history of malignant tumor of larynx -Those who need to continuously take Warfarin, Coumarin, Non-steroidal anti inflammatory drugs including Aspirin (above 325mg/d) or Steroid medication during clinical trial. - Those who have undergone gastric acid suppression surgery or gastric or duodenal surgery. - Those who have undergone major surgery that may affect gastric acid secretion, except surgery such as appendectomy, cholecystotomy and hysterectomy. - Those with Zollinger-Ellison syndrome and alcoholics, or those with a history of current drug abuse. - Those using a CPAP(Continuous Positive Airway Pressure) for treating sleep apnea symptoms. - Pregnant and lactating women. - A woman of childbearing expected to be pregnant (Menopausal women who are more than at least 12 months of age are considered non-childbearing women) - Those whe had participated in other clinical trial within 30 days before screening. - Those who are considered not suitable for this study by researcher.

Design outcomes

Primary

Measure	Time frame
Reflux Symptom Index (RSI);Reflux Finding Score (RFS)	—

Secondary

Measure	Time frame
Functional Outcomes of Sleep Questionnaire (FOSQ-10);Pittsburg Sleep Quality Index (PSQI)	—

Countries

Korea, Republic of

Contacts

Public ContactSung Kang

Kunkuk University Chungju Hospital

kkdin@naver.com+82-43-840-8280

Outcome results